Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.
Roche’s China shopping spree continues with $1B Rona obesity pact
Latest NewsRoche has licensed worldwide rights to Rona Therapeutics’ experimental ALK7-targeting RNA interference therapy for obesity and metabolic diseases, offering up to $100 million (about €89 million) in upfront and near-term payments, plus up to $1.06 billion (about €0.95 billion) in milestone payments.
Enodia lands $500M Pfizer deal to target proteins at the point of synthesis
Latest NewsParis-based Enodia Therapeutics is entering a partnership with big pharma Pfizer to discover and develop small molecules for targeted protein degradation at the point of synthesis with a deal that could potentially bring more than $500 million (€446 million) to the biotech company.
Elicera’s CAR-T clears detectable lymphoma in eight patients
Latest NewsSwedish biotech Elicera Therapeutics reported complete metabolic responses in eight of 12 patients treated with its experimental CAR-T therapy ELC-301 in the Phase 1 portion of its CARMA trial. Six remained in complete response at their latest assessment.
Desentum secures €28M for faster allergy immunotherapy
Latest NewsFinnish biotech Desentum has raised €28 million in an oversubscribed equity round to advance three allergy immunotherapy programs, with Phase 2 results for its lead birch pollen candidate expected before year-end.
What’s next for argenx, Europe’s autoimmune breakthrough?
Background, Latest NewsOver the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its autoimmune drug Vyvgart (efgartigimod alfa) in diseases such as generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). We caught up with CEO Karen Massey to discuss how she plans to build on this success after joining argenx in March 2023 and taking up the role of CEO at the start of this year.
Perfusion for next generation biosimilars
slider, Sponsored PublicationsPerfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.
Every process is different. Not the platform.
slider, Sponsored PublicationsFor CDMOs, flexible upstream platforms can help streamline process development while maintaining reproducibility and continuity across scales.
Newron plans heart tests to lift schizophrenia trial hold
Latest NewsItaly’s Newron Pharmaceuticals has disclosed that the FDA kept U.S. enrollment in a Phase 3 trial of its schizophrenia drug evenamide on hold, citing five deaths across all the drug’s clinical studies. The company will ask the agency to lift the hold by screening patients for hidden heart-rhythm disorders, including with genetic tests.
Alligator’s CFO takes the top job, Sensorion names finance chief and RQ Bio appoints new CMO
Latest NewsEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a CEO transition shaped by a strategic retreat, a finance hire ahead of a gene therapy trial and a medical appointment as an influenza antibody approaches the clinic.
ADC Therapeutics buys time for Zynlonta with $86.6M financing
Latest NewsSwiss biotech ADC Therapeutics has secured an $86.6 million (€77.5 million) financing agreement alongside debt and royalty deal amendments that extend its expected cash runway into 2029 and remove a potential obstacle to a takeover.